Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with recent trials suggesting …

The ACC’s Heart Failure and SGLT2is: The New Pillar in Care Initiative is designed to provide practical guidance for clinicians on the implementation of sodium-glucose cotransporter-2 …

SGLT2 inhibitors were added to heart failure guidelines in 2022. Dapagliflozin and empagliflozin have shown benefits in patients with HFrEF, HFpEF, and HFmrEF with or without diabetes.7 …

Mar 26, 2025 · SGLT2 inhibitors offer major heart benefits for non-diabetic people with heart failure. They lower the chances of being hospitalized for heart issues and reduce the risk of …

Jun 3, 2025 · SGLT2 inhibitors have become an important class of medication in managing heart failure. Initially developed to treat diabetes, these drugs have shown clear benefits for patients …

ABSTRACT Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-di-rected medical therapy in heart failure (HF) with reduced ejection fraction with …

Jun 1, 2025 · Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors are oral antidiabetic agents that have shown significant improvements in cardiovascular and renal outcomes …

Start dapagliflozin or empagliflozin on the advice of a heart failure specialist. Dapagliflozin and empagliflozin are recommended as options for treating symptomatic chronic heart failure with …

Abstract Background Heart failure (HF) is a clinical diagnosis of a condition that develops secondary to either left ventricular systolic or diastolic functions. Lately, inhibitors of sodium …

This systematic review and meta-analysis assesses associations of sodium glucose cotransporter-2 inhibitors (SGL2i) with functional capacity and quality of life outcomes among …